Heparin-induced thrombocytopenia: What clinicians need to know

Thrombosis and Haemostasis

Volumn 101, Issue 2, 2009, Pages 279-283

  Chong, Beng H ^a,b   Isaacs, Arend ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT; AUTOANTIBODY; CHONDROITIN SULFATE; DERMATAN SULFATE; HEPARAN SULFATE; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; PIPECOLIC ACID DERIVATIVE; POLYSACCHARIDE; RECOMBINANT PROTEIN; THROMBOCYTE FACTOR 4;

ANAPHYLAXIS; ANTICOAGULATION; ARTICLE; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; LABORATORY TEST; LOW DRUG DOSE; PRIORITY JOURNAL; PROPHYLAXIS; SKIN DEFECT; SKIN MANIFESTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; IMMUNOLOGY; REVIEW;

ANTICOAGULANTS; AUTOANTIBODIES; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG MONITORING; HEPARIN; HEPARITIN SULFATE; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PLATELET COUNT; PLATELET FACTOR 4; POLYSACCHARIDES; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOSIS; WARFARIN;

EID: 62449101286     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0659     Document Type: Article

References (18)

1. Chong BH. Heparin-induced thrombocytopenia, In: Platelets (2nd Edition). Academic Press, New York 2007: 861-866.
2. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-1478.
3. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (Suppl): 340S-380S.
4. Warkentin TE, Heddlc NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-157.
5. Newman P, Chong BH. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resulting activation. Blood 2000; 96: 182-187.
6. Savi P, Chong BH, Greinacher A, et al. Effect of Fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicentre study with unfractionated heparin. Blood 2005; 105: 139-144.
7. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular weight heparin-induced HIT: a case report. Thromb Haemost 2008; 99: 779-781.
8. Schindewolf M, Lindhoff-Last E. Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. Thromb Haemost 2008; 100: 168-169.
9. Majed AR, Warkentin TE, Axelson M, et al. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin "flushes". Thromb Haemost 2007; 98: 1139-1140.
10. Chong BH, Du X-P, Berndt MC, et al. Characterisation of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991; 77: 2190-2199.
11. Gustavo OBF. Crespo EM, Becker RC, et al for the Complications after thrombocytopenia caused by heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94-102.
12. Price EA, Hayward CPM, Moffat KA, et al. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. Thromb Haemost 2007; 98: 1357-1361.
13. Chong BH, Gallus AS, Cade J, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost, 2001: 86: 1170-1175.
14. Magnani HN, Gallus A. Heparin-induced throm-bocytopenia(HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
15. Earner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Throm Haemost 2001; 85: 950-957.
16. Keng TB, Chong BH. Heparin-induced thrombocytopenia and thrombosis syndrome: irrvivo cross-reac-tivity with danaparoid and successful treatment with r-Hirudin. Brit J Haemotol 2001; 114: 394-396.
17. Warkentin TE. Fondaparinux versus direct thrombin inhibitor therapy for the managemetnof heprin-in-duced thrombocytopenia (HIT) - Bridging the River Coumarin. Thromb Haemost 2008; 99: 2-3.
18. Yobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.